147 related articles for article (PubMed ID: 32278508)
1. [Kanamycin-induced ototoxicity during treatment of multidrug-resistant tuberculosis].
Poka-Mayap V; Balkissou Adamou D; Pefura-Yone EW; Kuaban C
Rev Mal Respir; 2020 May; 37(5):369-375. PubMed ID: 32278508
[TBL] [Abstract][Full Text] [Related]
2. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.
Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Leufkens HG; Mantel-Teeuwisse AK
BMC Pharmacol Toxicol; 2015 Dec; 16():36. PubMed ID: 26654443
[TBL] [Abstract][Full Text] [Related]
3. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
Ramma L; Nhokwara PT; Rogers C
S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis.
Ghafari N; Court R; Chirehwa MT; Wiesner L; Petersen L; Maartens G; Gumbo T; McIlleron H; Ramma L
Int J Audiol; 2020 Mar; 59(3):219-223. PubMed ID: 31739701
[No Abstract] [Full Text] [Related]
5. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Sogebi OA; Adefuye BO; Adebola SO; Oladeji SM; Adedeji TO
Auris Nasus Larynx; 2017 Aug; 44(4):404-410. PubMed ID: 27832910
[TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
[TBL] [Abstract][Full Text] [Related]
7. Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon.
Mpoh MM; Deli V; Daniel TT; Salvo F
Int J Mycobacteriol; 2023; 12(2):168-174. PubMed ID: 37338479
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Pre-Existing Hearing Loss Among Patients With Drug-Resistant Tuberculosis in South Africa.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Am J Audiol; 2020 Jun; 29(2):199-205. PubMed ID: 32320639
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.
Hong H; Budhathoki C; Farley JE
Int J Tuberc Lung Dis; 2018 Jun; 22(6):667-674. PubMed ID: 29862952
[TBL] [Abstract][Full Text] [Related]
10. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
[No Abstract] [Full Text] [Related]
12. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients.
Harris T; Bardien S; Schaaf HS; Petersen L; De Jong G; Fagan JJ
S Afr Med J; 2012 May; 102(6 Pt 2):363-6. PubMed ID: 22668907
[TBL] [Abstract][Full Text] [Related]
13. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
[TBL] [Abstract][Full Text] [Related]
14. Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose.
Hong H; Dowdy DW; Dooley KE; Francis HW; Budhathoki C; Han HR; Farley JE
Int J Tuberc Lung Dis; 2020 Jan; 24(1):65-72. PubMed ID: 32005308
[No Abstract] [Full Text] [Related]
15. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
Sturdy A; Goodman A; José RJ; Loyse A; O'Donoghue M; Kon OM; Dedicoat MJ; Harrison TS; John L; Lipman M; Cooke GS
J Antimicrob Chemother; 2011 Aug; 66(8):1815-20. PubMed ID: 21642291
[TBL] [Abstract][Full Text] [Related]
17. OTOTOXICITY OF ANTIMYCOBACTERIAL THERAPY: MANIFESTATIONS, MECHANISMS OF MANAGEMENT AND CONTROL.
Makoyda I; Ostrovskyy М; Shevchuk-Budz U; Molodovets О; Zuban A
Wiad Lek; 2023; 76(12):2587-2592. PubMed ID: 38290021
[TBL] [Abstract][Full Text] [Related]
18. Cycloserine Induced Suicidal Tendencies and Kanamycin Induced Ototoxicity in Indian MDR-TB Patient: A Case Report.
Jangra MS; Chhabra M
Curr Drug Saf; 2018; 13(3):211-213. PubMed ID: 29866015
[TBL] [Abstract][Full Text] [Related]
19. The safety and tolerability of the second-line injectable antituberculosis drugs in children.
Garcia-Prats AJ; Schaaf HS; Hesseling AC
Expert Opin Drug Saf; 2016 Nov; 15(11):1491-1500. PubMed ID: 27548570
[TBL] [Abstract][Full Text] [Related]
20. Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis.
Sharma V; Bhagat S; Verma B; Singh R; Singh S
Iran J Otorhinolaryngol; 2016 May; 28(86):203-8. PubMed ID: 27429949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
